Liquidia and Pharmosa Biopharm Enters into Exclusive Licensing Agreement for $225M to Develop and Commercialize L606 in North America
Shots:
- Under the terms of the agreement, Pharmosa will receive an up front payment of $10M along with ~$215M as milestone payments and royalties on net sales of L606. In addition, Pharmosa to receive $10M option payment for each additional indication and additional product approved
- Pharmosa will manufacture clinical and commercial supplies and support Liquidia in establishing a global supply chain development and commercialization of L606 in North America
- L606, an inhaled, sustained-release formulation of Treprostinil, utilizes Pharmosa’s proprietary liposomal formulation. It is being evaluated in a clinical study for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease
Ref: Globe NewsWire | Image: Liquidia
Related News:- GSK Amends its Development and Commercialization Agreement with Liquidia for Inhaled Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
